<DOC>
	<DOCNO>NCT01582217</DOCNO>
	<brief_summary>The purpose study ass 1-year rate ischemic bleeding complication patient whose dual antiplatelet therapy regimen post-PCI determine use clinical algorithm include clinical risk platelet reactivity chronic clopidogrel therapy .</brief_summary>
	<brief_title>Patients Undergoing Percutaneous Coronary Intervention ( PCI ) Through Optimal Platelet Inhibition</brief_title>
	<detailed_description>Prospective multicenter registry . Patients already chronic dual antiplatelet therapy aspirin clopidogrel assess ( 1 ) clinical risk factor future bleed ischemic complication , ( 2 ) on-treatment platelet reactivity measure VerifyNow P2Y12 assay ( Accumetrics , Inc. , San Diego , CA , USA ) . These consider utilization clinical algorithm determine dual antiplatelet regimen post-PCI ( aspirin combination 1. clopidogrel , 2. prasugrel 5mg daily , 3. prasugrel 10mg daily ) .</detailed_description>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>The subject provide informed write . The subject must â‰¥ 18 year age ( minimum age require local regulation ) time enrollment . Patient establish chronic clopidogrel therapy he/she return PCI , component DAPT determine clinical decision algorithm local standard care . The subject willing able cooperate study procedure require followup . Patients cardiogenic shock exclude . The subject participate investigational device drug study . Subject must complete follow phase previous study least 30 day prior enrolment study . Pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Bleeding</keyword>
	<keyword>Risk Score</keyword>
	<keyword>Outcomes</keyword>
	<keyword>Prasugrel</keyword>
</DOC>